<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029548</url>
  </required_header>
  <id_info>
    <org_study_id>ISS OBS T-003</org_study_id>
    <nct_id>NCT01029548</nct_id>
  </id_info>
  <brief_title>Observational Study on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects</brief_title>
  <acronym>ISS OBS T-003</acronym>
  <official_title>Observational Study With Additional Diagnostic Procedures on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ensoli, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Superiore di Sanità</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is designed as a prospective observational study directed at evaluating the
      frequency, magnitude, quality and persistence (primary endpoint) of the anti-Tat immune
      response in HIV-1 infected asymptomatic individuals, and to prospectively evaluate the
      immunological, virological and clinical outcome of anti-Tat positive versus anti-Tat negative
      drug naїve subjects (secondary endpoint) in order to determine the impact of anti-Tat
      immunity on HIV disease progression as well as the potential use of anti-Tat immune response
      assessment for the clinical and therapeutic management of infected patients. This survey
      provided important information for the design, planning and conduction of future therapeutic
      vaccine trials based on the HIV-1 Tat protein in asymptomatic subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Specific humoral and cellular immune responses to Tat will be monitored by assessing anti-Tat specific antibodies in sera, proliferative response (CFSE) and production of γIFN, IL-4 and IL-2 (Elispot) by peripheral blood mononuclear cells.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The decline of CD4+ T cells count, the increase of the HIV plasma viral load or the occurrence of AIDS-defining events will be assessed to determine the progression to disease</measure>
  </secondary_outcome>
  <enrollment type="Actual">73</enrollment>
  <condition>HIV Infections</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood, serum, PBMCs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Asymptomatic HIV infected individuals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be clinically asymptomatic HIV-1 infected individuals with CD4+ T cell counts
             ≥400/μL

          -  To be naïve for antiretroviral therapy

          -  Levels of plasma viremia ≤100,000 copies/ml at baseline

          -  Age ≥ 18 years

          -  Signed informed consent

        Exclusion Criteria:

          -  Current therapy with immunomodulators or immunosuppressive drugs or chemotherapy for
             neoplastic disorders

          -  Concomitant treatment for HBV or HCV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Mazzotta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.M. Annunziata Hospital Florence, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Pastore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Bari</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florio Ghinelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital-University of Ferrara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Esposito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital-University of Modena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Galli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>L.Sacco Hospital - MI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrizio Soscia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>S.M. Goretti Hospital Latina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guido Palamara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Gallicano Hospital - Rome</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adriano Lazzarin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Raffaele Hospital - Milan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giampiero Carosi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spedali Civili - Brescia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Di Perri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amedeo di Savoia Hospital - Turin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S.M. Goretti Hospital</name>
      <address>
        <city>Latina</city>
        <state>Rome</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital-University of Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.M. Annunziata Hospital</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L. Sacco Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital-University of Modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Gallicano Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giovanni Di Perri</name>
      <address>
        <city>Turin</city>
        <zip>10149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.hiv1tat-vaccines.info</url>
  </link>
  <link>
    <url>http://www.iss.it/aids/</url>
  </link>
  <reference>
    <citation>Ensoli B, Fiorelli V, Ensoli F, Cafaro A, Titti F, Buttò S, Monini P, Magnani M, Caputo A, Garaci E. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS. 2006 Nov 28;20(18):2245-61. Review.</citation>
    <PMID>17117011</PMID>
  </reference>
  <reference>
    <citation>Rezza G, Fiorelli V, Dorrucci M, Ciccozzi M, Tripiciano A, Scoglio A, Collacchi B, Ruiz-Alvarez M, Giannetto C, Caputo A, Tomasoni L, Castelli F, Sciandra M, Sinicco A, Ensoli F, Buttò S, Ensoli B. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis. 2005 Apr 15;191(8):1321-4. Epub 2005 Mar 14.</citation>
    <PMID>15776379</PMID>
  </reference>
  <reference>
    <citation>Rodman TC, To SE, Hashish H, Manchester K. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7719-23.</citation>
    <PMID>7689227</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Cafaro A, Monini P, Marcotullio S, Ensoli F. Challenges in HIV Vaccine Research for Treatment and Prevention. Front Immunol. 2014 Sep 8;5:417. doi: 10.3389/fimmu.2014.00417. eCollection 2014. Review.</citation>
    <PMID>25250026</PMID>
  </reference>
  <reference>
    <citation>Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology. 2015 Apr 29;12:33. doi: 10.1186/s12977-015-0151-y.</citation>
    <PMID>25924841</PMID>
  </reference>
  <reference>
    <citation>Cafaro A, Tripiciano A, Sgadari C, Bellino S, Picconi O, Longo O, Francavilla V, Buttò S, Titti F, Monini P, Ensoli F, Ensoli B. Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine. Expert Opin Biol Ther. 2015;15 Suppl 1:S13-29. doi: 10.1517/14712598.2015.1021328. Epub 2015 Jun 22. Review.</citation>
    <PMID>26096836</PMID>
  </reference>
  <reference>
    <citation>Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez MJ, Campagna M, Scaramuzzi D, Iori C, Esposito R, Mussini C, Ghinelli F, Sighinolfi L, Palamara G, Latini A, Angarano G, Ladisa N, Soscia F, Mercurio VS, Lazzarin A, Tambussi G, Visintini R, Mazzotta F, Di Pietro M, Galli M, Rusconi S, Carosi G, Torti C, Di Perri G, Bonora S, Ensoli F, Garaci E. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One. 2010 Nov 11;5(11):e13540. doi: 10.1371/journal.pone.0013540.</citation>
    <PMID>21085635</PMID>
  </reference>
  <reference>
    <citation>Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A, Nappi F, Longo O, Bellino S, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone P, Leone P, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MP, Titti F, Banci L, Dallocchio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, Ensoli B. HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies. PLoS One. 2012;7(11):e48781. doi: 10.1371/journal.pone.0048781. Epub 2012 Nov 13.</citation>
    <PMID>23152803</PMID>
  </reference>
  <results_reference>
    <citation>Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N, Lazzarin A, Tambussi G, Nozza S, Torti C, Focà E, Palamara G, Latini A, Sighinolfi L, Mazzotta F, Di Pietro M, Di Perri G, Bonora S, Mercurio VS, Mussini C, Gori A, Galli M, Monini P, Cafaro A, Ensoli F, Ensoli B. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology. 2014 Jun 24;11:49. doi: 10.1186/1742-4690-11-49.</citation>
    <PMID>24961156</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2009</study_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Superiore di Sanità</investigator_affiliation>
    <investigator_full_name>Barbara Ensoli, MD</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Therapeutic Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

